(Q43830570)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

Vaccination with human papillomavirus type 16-derived peptides using a tattoo device (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Ingrid Poláková

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Dana Pokorná

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Martina Kindlová

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Martina Dusková

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Viera Ludvíková

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Pavel Gabriel

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Lud'a Kutinová

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Martin Müller

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

English

0 references

publication date

16 April 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

3519-3529

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19464530%20AND%20SRC:MED&resulttype=core&format=json

HPV protein/peptide vaccines: from animal models to clinical trials

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Peptide-based therapeutic vaccines for allergic and autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Peptide-based vaccination: where do we stand?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Rational Peptide-based vaccine design for cancer immunotherapeutic applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Peptide-based vaccination for colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Self-adjuvanting lipopeptide vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Response of mouse skin to tattooing: use of SKH-1 mice as a surrogate model for human tattooing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Prophylactic DNA immunization against multiple papillomavirus types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Lipid–protamine–DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Development of Th1-mediated CD8+ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Vaccination with human papillomavirus type 16 E7 peptide with CpG oligonucleotides for prevention of tumor growth in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient HPV16-associated tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Chimeric hepatitis B core antigen particles containing B- and Th-epitopes of human papillomavirus type 16 E7 protein induce specific antibody and T-helper responses in immunised mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073

N-terminus of a major allergen, Alt a I, of Alternaria alternata defined to be an epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.073